JP2011513437A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011513437A5 JP2011513437A5 JP2010550000A JP2010550000A JP2011513437A5 JP 2011513437 A5 JP2011513437 A5 JP 2011513437A5 JP 2010550000 A JP2010550000 A JP 2010550000A JP 2010550000 A JP2010550000 A JP 2010550000A JP 2011513437 A5 JP2011513437 A5 JP 2011513437A5
- Authority
- JP
- Japan
- Prior art keywords
- moiety
- cancerous cells
- compound
- prooxidant
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 26
- 210000004027 cell Anatomy 0.000 claims 23
- 230000003244 pro-oxidative effect Effects 0.000 claims 13
- 230000001939 inductive effect Effects 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- 230000002438 mitochondrial effect Effects 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 210000003470 mitochondria Anatomy 0.000 claims 6
- 230000000861 pro-apoptotic effect Effects 0.000 claims 6
- 230000034994 death Effects 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 230000006907 apoptotic process Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical group OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000003642 reactive oxygen metabolite Substances 0.000 claims 3
- LCFWOFKPFDWYLR-CEFNRUSXSA-N alpha-tocopheryloxyacetic acid Chemical compound OC(=O)COC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C LCFWOFKPFDWYLR-CEFNRUSXSA-N 0.000 claims 2
- 150000001768 cations Chemical class 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- -1 triphenylphosphonium cation Chemical class 0.000 claims 2
- 150000003712 vitamin E derivatives Chemical class 0.000 claims 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical group OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 claims 1
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 235000017471 coenzyme Q10 Nutrition 0.000 claims 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229940035936 ubiquinone Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2008901261A AU2008901261A0 (en) | 2008-03-14 | Mitochondrially Delivered Anti-Cancer Compounds | |
| AU2008901261 | 2008-03-14 | ||
| PCT/AU2009/000312 WO2009111846A1 (en) | 2008-03-14 | 2009-03-16 | Mitochondrially delivered anti-cancer compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011513437A JP2011513437A (ja) | 2011-04-28 |
| JP2011513437A5 true JP2011513437A5 (enExample) | 2013-05-02 |
| JP5616798B2 JP5616798B2 (ja) | 2014-10-29 |
Family
ID=41064682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010550000A Active JP5616798B2 (ja) | 2008-03-14 | 2009-03-16 | ミトコンドリア由来の抗ガン化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8598145B2 (enExample) |
| EP (1) | EP2265623B1 (enExample) |
| JP (1) | JP5616798B2 (enExample) |
| KR (1) | KR101642157B1 (enExample) |
| CA (1) | CA2734208C (enExample) |
| NZ (1) | NZ602579A (enExample) |
| WO (1) | WO2009111846A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012140660A1 (en) | 2011-04-14 | 2012-10-18 | Exalenz Bioscience Ltd. | Methods for diagnosis, prognosis, monitoring and treatment of hepatocellular carcinoma |
| WO2012174287A1 (en) * | 2011-06-15 | 2012-12-20 | The Board Of Regents Of The University Of Texas System | Luminescent nanoparticle compositions |
| HK1200459A1 (en) | 2011-09-19 | 2015-08-07 | Gencia Corporation | Modified creatine compounds |
| WO2013181488A2 (en) * | 2012-06-01 | 2013-12-05 | The Ohio State University Research Foundation | Inhibition of leukemic stem cells by pp2a activating agents |
| KR101764991B1 (ko) * | 2013-04-24 | 2017-08-10 | 스마트 브레인 에스.알.오. | 특히 높은 her2 단백질 농도를 갖는 신생물성 질환의 치료를 위한 타목시펜 유도체 |
| US10953110B2 (en) | 2014-04-25 | 2021-03-23 | Board Of Regents, The University Of Texas System | Dual emissive metal nanoparticles as ratiometric pH indicators |
| WO2016144637A1 (en) * | 2015-03-06 | 2016-09-15 | The Children's Hospital Of Philadelphia | Tocopheryloxyacetate ester-based co-drug conjugates |
| CZ307146B6 (cs) * | 2015-03-31 | 2018-02-07 | Kkcg Se | Trifenylfosfoniové analogy biguanidu, způsob jejich přípravy a jejich použití jako léčiva |
| CA3004059A1 (en) | 2015-11-04 | 2017-05-11 | Prescient Pharma Llc | Anti-aging compositions and methods for using same |
| KR102361131B1 (ko) * | 2020-02-25 | 2022-02-10 | 경희대학교 산학협력단 | 항생제 내성 균주에 대해 항균활성을 갖는 항균용 조성물 |
| CN116249557A (zh) * | 2020-10-22 | 2023-06-09 | 白雁生物技术公司 | 包含抗癌药物的线粒体及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030069208A1 (en) * | 1997-11-25 | 2003-04-10 | University Of Otago | Mitochondrially targeted antioxidants |
| US6331532B1 (en) * | 1998-11-25 | 2001-12-18 | University Of Otago | Mitochondrially targeted antioxidants |
| EP1254130B1 (en) | 2000-02-11 | 2008-01-02 | Research Development Foundation | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
| AUPQ605800A0 (en) * | 2000-03-06 | 2000-03-30 | Silverbrook Research Pty Ltd | Printehead assembly |
| US20040241058A1 (en) * | 2001-05-17 | 2004-12-02 | Caro Colin G | Production and processing plant with a rigid pipe portion curving in three dimensions |
| EP1664069B8 (en) | 2003-08-22 | 2015-07-01 | Antipodean Pharmaceuticals, Inc. | Mitoquinone derivatives used as mitochondrially targeted antioxidants |
| RU2007107359A (ru) | 2004-07-28 | 2008-09-10 | ЭсДи ФАРМАСЬЮТИКАЛЗ, ИНК. (US) | Стабильная инъецируемая композиция альфа-токоферилсукцината, его аналогов и солей |
| KR100556527B1 (ko) * | 2004-11-04 | 2006-03-06 | 삼성전자주식회사 | 트렌치 소자 분리막 형성 방법 및 불휘발성 메모리 장치의제조 방법 |
| US20080095834A1 (en) | 2005-03-02 | 2008-04-24 | Volkmar Weissig | Mitochondriotropic Phospholipid Vesicles |
| RU2318500C2 (ru) * | 2005-10-18 | 2008-03-10 | Общество С Ограниченной Ответственностью "Митотехнология" | Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели |
| AU2007295877B2 (en) | 2006-09-15 | 2013-04-18 | Cancure Limited | Pro-oxidant anti-cancer compounds |
| JP4930026B2 (ja) * | 2006-12-13 | 2012-05-09 | 富士ゼロックス株式会社 | 積層体、無端状ベルト、定着装置及び画像形成装置 |
| DE102007025423A1 (de) | 2007-05-30 | 2008-12-04 | Friedrich-Schiller-Universität Jena | Triphenylphosphonium-Derivate zum gezielten Transport und Freisetzen von Substanzen in Mitochondrien sowie Verfahren zu deren Verwendung |
-
2009
- 2009-03-16 JP JP2010550000A patent/JP5616798B2/ja active Active
- 2009-03-16 NZ NZ602579A patent/NZ602579A/en not_active IP Right Cessation
- 2009-03-16 KR KR1020107022874A patent/KR101642157B1/ko active Active
- 2009-03-16 US US12/922,525 patent/US8598145B2/en not_active Ceased
- 2009-03-16 US US14/955,297 patent/USRE47300E1/en not_active Expired - Fee Related
- 2009-03-16 EP EP09720005.9A patent/EP2265623B1/en not_active Not-in-force
- 2009-03-16 WO PCT/AU2009/000312 patent/WO2009111846A1/en not_active Ceased
- 2009-03-16 CA CA2734208A patent/CA2734208C/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011513437A5 (enExample) | ||
| EA200802012A1 (ru) | Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением | |
| JP2016517434A5 (enExample) | ||
| JP2010525050A5 (enExample) | ||
| JP2020514412A5 (enExample) | ||
| WO2009111846A4 (en) | Mitochondrially delivered anti-cancer compounds | |
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| NZ595767A (en) | Composition for the treatment of prostate cancer | |
| WO2019130215A1 (en) | Cannabis compositions for the treatment of inflammatory skin disorders | |
| WO2014180239A1 (zh) | 一种治疗重症高原病的药物组合物 | |
| BR0316057A (pt) | Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit | |
| NO20080244L (no) | Doseringsstyring for prasugrel | |
| JP2016505050A5 (enExample) | ||
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| MX2025000038A (es) | Composiciones farmacéuticas que comprenden isotretinoína y procesos para la preparación y usos de las mismas | |
| CN101933963A (zh) | 一种治疗头痛的鼻用原位凝胶剂 | |
| CN101439160A (zh) | 玉米提取物防治肿瘤的用途 | |
| CN105535003A (zh) | 金盏花苷e在制备治疗抗肿瘤药物中的用途 | |
| TWI469784B (zh) | 可治療癌症之藥學組合物 | |
| MX2010006310A (es) | O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor. | |
| RU2572504C1 (ru) | Способ лечения лучевой сиалоаденопатии | |
| CN101856359A (zh) | 一种抗急性髓系白血病的药物组合物 | |
| CN103371987B (zh) | 漆酚化合物在制备抑制肾脏组织纤维化的药物中的用途 | |
| CN100584854C (zh) | 圆锥绣球有效部位、其制备方法及其组合物与用途 | |
| KR20120102214A (ko) | 한방복합 생약 소염 진통 외용제 |